Aurora Private Wealth Inc. Makes New Investment in Pfizer Inc. (NYSE:PFE)

Aurora Private Wealth Inc. bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 38,926 shares of the biopharmaceutical company's stock, valued at approximately $986,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Lecap Asset Management Ltd. lifted its stake in Pfizer by 20.9% in the 1st quarter. Lecap Asset Management Ltd. now owns 81,193 shares of the biopharmaceutical company's stock valued at $2,057,000 after buying an additional 14,050 shares in the last quarter. Horizon Bancorp Inc. IN lifted its position in shares of Pfizer by 1.0% in the first quarter. Horizon Bancorp Inc. IN now owns 69,047 shares of the biopharmaceutical company's stock valued at $1,750,000 after acquiring an additional 664 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Pfizer by 4.3% in the first quarter. International Assets Investment Management LLC now owns 235,121 shares of the biopharmaceutical company's stock valued at $5,495,000 after acquiring an additional 9,630 shares in the last quarter. Embree Financial Group boosted its stake in shares of Pfizer by 29.1% in the first quarter. Embree Financial Group now owns 12,524 shares of the biopharmaceutical company's stock worth $317,000 after acquiring an additional 2,826 shares during the last quarter. Finally, Keudell Morrison Wealth Management increased its position in shares of Pfizer by 13.4% during the first quarter. Keudell Morrison Wealth Management now owns 18,110 shares of the biopharmaceutical company's stock worth $459,000 after purchasing an additional 2,147 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.2%

Pfizer stock traded up $0.04 during mid-day trading on Thursday, hitting $24.30. The company had a trading volume of 31,721,433 shares, compared to its average volume of 41,253,043. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business has a fifty day moving average of $23.38 and a 200 day moving average of $24.87. The stock has a market cap of $138.18 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm posted $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. Pfizer's dividend payout ratio is presently 124.64%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.